SHH and neoplasm: While SHH pathway inhibition has proven beneficial against basal cell carcinoma (Sekulic et al. 2012, 2017), it has proven detrimental in other cancers, such as PDAC, where enhanced tumour progression and aggressiveness was observed in both preclinical and clinical trials (Madden 2012, Catenacci et al. 2015).